Last updated 2026-07-27
- Went public on NASDAQ (BCLI), Jun 2024
- Raised $16M grant, Jun 2017
- Raised $5M grant, Jun 2014
Total raised
$42.7M
Last: PIPE 2026-02
Stage
Public
Founded
2000
Headcount
19
HQ
New York, United States
Sector
Health Tech & Life Sciences
About
BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing autologous adult stem cell therapies for debilitating neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), and Alzheimer's disease (AD). The company's proprietary NurOwn® platform uses a patient's own mesenchymal stem cells (MSCs) to generate neurotrophic factor-secreting cells (MSC-NTF cells) designed to modulate neuroinflammation and promote neuroprotection. BrainStorm holds exclusive worldwide licensing rights for the NurOwn® technology platform.
Funding history · 21 rounds · $42.7M total
2026-02
PIPE
Undisclosed
2025-03
PIPE
Undisclosed
2024-06
PIPE
Undisclosed
2024-04
Follow-on PO
Undisclosed
2023-07
Follow-on PO
Undisclosed
2020-08
Follow-on PO
Undisclosed
2020-03
Follow-on PO
Undisclosed
2019-08
Follow-on PO
Undisclosed
2019-08
PIPE
Undisclosed
2018-09
Follow-on PO
Undisclosed
2018-06
PIPE
Undisclosed
2017-06
Grant
$16.0M
2017-05
Grant
$2.1M
2014-11
Grant
$1.1M
2014-06
Grant
$5.0M
2014-05
PIPE
$10.5M
★ Post IPO Debt Capital
2014-04
PIPE
$1.6M
★ SEC Investors
2014-01
Grant
$600K
2013-11
Grant
$800K
2012-06
PIPE
$5.0M
★ Post IPO Debt Capital
2003-09
Follow-on PO
Undisclosed
Headcount over time
From 18 (2018-09) to 31 (2026-03) · +13 (+72%) · 50 points · source: Finder history + radar grounding
Q&A
- What is BrainStorm Cell Therapeutics' primary focus?
- BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous adult stem cell therapies for debilitating neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), and Alzheimer's disease (AD).
- What is BrainStorm Cell Therapeutics' proprietary technology platform?
- BrainStorm's proprietary NurOwn® platform uses a patient's own mesenchymal stem cells (MSCs) to generate neurotrophic factor-secreting cells (MSC-NTF cells) designed to modulate neuroinflammation and promote neuroprotection.
- When did BrainStorm Cell Therapeutics become a public company?
- BrainStorm Cell Therapeutics went public on NASDAQ in October 2003.
- What was the most recent funding round for BrainStorm Cell Therapeutics?
- The most recent funding round for BrainStorm Cell Therapeutics was a PIPE round in February 2026, raising $1,000,000.
- What was the amount raised in BrainStorm Cell Therapeutics' Public Offering in June 2024?
- In June 2024, BrainStorm Cell Therapeutics completed a Public Offering that raised $4,000,000.
- What is the current employee count for BrainStorm Cell Therapeutics?
- BrainStorm Cell Therapeutics has an employee count in the 11-50 range.
- What is the status of BrainStorm's NurOwn® Phase 3b trial for ALS?
- In May 2025, BrainStorm received FDA clearance to initiate the Phase 3b trial of NurOwn® for ALS.
- What recent strategic partnership did BrainStorm Cell Therapeutics secure for NurOwn® manufacturing?
- In May 2025, BrainStorm secured a manufacturing partnership with Minaris for the upcoming NurOwn® Phase 3b ALS clinical trials.
- What is the status of BrainStorm Cell Therapeutics' listing on stock exchanges?
- In July 2025, BrainStorm Cell Therapeutics announced its delisting from Nasdaq and transition to the OTCQB Venture Market, where its ticker is BCLI.
- What was a significant finding from BrainStorm's Expanded Access Program for ALS patients?
- In June 2025, BrainStorm announced new survival data from its Expanded Access Program cohort, showing that 90% of ALS patients survived over 5 years with NurOwn®.
Team · 1
Daniel Offen
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatientsLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
degenerative-diseasesstem-cellstherapeuticsbiotechnologyneurologyhospitalsparkinsoncell-therapymedical-technologiesautismcns-disordersdrug-discoverymultiple-sclerosis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainstorm-cell.com |
|---|---|
| linkedin.com/company/2665125 | |
| facebook.com/BrainStormCell |
Identifiers & details
| Legal name | BrainStorm Cell Therapeutics Inc. |
|---|---|
| Founded | 2000 |
| Employees (exact) | 19 |
| Offices | New York |
| Market cap | $6.1M |
| Status reason | Public on NASDAQ on Oct 2003; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Delisting from Nasdaq | 2025-10 | NASDAQ | ||
| Listing on OTCQB Venture Market | 2025-10 | OTCQB | BCLI | |
| Registered Direct Offering | 2024-06 | NASDAQ | BCLI | $4.0M |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513601021 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2004-10-25 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | בזל 12 פתח תקווה |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-19 | דו~ח שנתי |